Participating in research helps further knowledge that impacts generations to come.
The FDA is reviewing two COVID-19 vaccines for emergency use authorization. Learn about how researchers were able to develop and test these vaccines so quickly with safety as a priority.
Dr. Cynthia Gay is leading a research team in a phase 3 vaccine trial at UNC. Learn what it means to participate in a vaccine trial and see what goes on behind the scenes of a large clinical trial with testing sites across the country.
UNC Health is now collecting convalescent plasma donations from COVID-19 survivors. The plasma of survivors contains the antibodies that fought off coronavirus and could help others who have not yet developed their own antibodies to fight the virus.
The Baric Lab at UNC Gillings School of Public Health, in partnership with Gilead Sciences, has found that Remdesivir has been effective in treating patients with COVID-19.
A drug called EIDD-2801 has shown positive outcomes on lung function in mice when used as a prophylactic and as a treatment during infection.
During a time of uncertainty for many Americans, some are stepping forward to get involved in research that could help develop a vaccine for coronavirus. Jennifer Haller, a Seattle native, was the first person to receive an experimental coronavirus vaccine developed by the NIH and Moderna Inc.
Intravaginal rings are a one-size-fits-all product, but Rahina Benhabbour wanted to change that. Using 3D printing for her startup company AnelleO, she developed an alternative that could change and personalize women’s health therapies.
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.